Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 107Genitourinary 5Gynecologic 2Gastrointestinal 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1Lymphoid 1Endocrine 1Classical hematology 1CNS 1

Conditions

Endometrial Neoplasms 8Ovarian Neoplasms 7Fallopian Tube Neoplasms 4Recurrence 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Neoplasms 2Breast Neoplasms 2Phase IB 1Multiple Myeloma 1Lung Neoplasms 1Endometrial Hyperplasia 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Advanced, Persistent, or Recurrent Endometrial Cancer 1

Interventions

pembrolizumab 33Paclitaxel 27Cyclophosphamide 25Carboplatin 23olaparib 21Fulvestrant 15fludarabine 14Trastuzumab 14aldesleukin 13Docetaxel 13Early Intervention, Educational 12Surveys and Questionnaires 11veliparib 10palbociclib 10Methods 10Gemcitabine 10Blood Specimen Collection 10Nivolumab 9Flow Cytometry 9Biopsy 9Bevacizumab 9sargramostim 8niraparib 7liposomal doxorubicin 7Therapeutics 7Taxes 7Standard of Care 7Psychiatric Rehabilitation 7Magnetic Resonance Spectroscopy 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Everolimus × Gynecologic × Clear all
NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting
500 enrolled
BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Avera McKennan Hospital & University Health Center

Phase 1 Completed
14 enrolled 12 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡